International Journal of Innovations & Research Analysis (IJIRA)
ISSN :2583-0295, Impact Factor: 5.449, Volume 03, No. 04(II), October- December, 2023, pp 37-40

ARE WE MISSING THE TARGET? CARDIO-PULMONARY MICROVASCULAR DYSFUNCTION

Dr. Rajkumar Gupta*
Dr. Suman Gupta**
Parkhi Gupta***
Dr. Anand Agarwal****
Divyanshu Prajapati*****

ABSTRACT

Long COVID, characterized by persistent symptoms following SARS-CoV-2 infection, remains an enigmatic clinical entity with debilitating consequences for millions globally. While much focus has been on the viral aspects and pulmonary sequelae, a growing body of evidence suggests that cardio-pulmonary microvascular dysfunction might be a central, yet under-recognized, driver of multi-organ damage in Long COVID. This review explores the current understanding of Long COVID's pathophysiology, focusing on the potential role of microvascular dysfunction. It reviews clinical evidence supporting this hypothesis, including persistent exercise intolerance, dyspnea, cognitive impairment, and fatigue. Further, it delves into the complexities of multidisciplinary management in Long COVID, emphasizing the need for a holistic approach that addresses microvascular dysfunction alongside other contributing factors. Cardio-pulmonary microvascular dysfunction (CMD and PMD) has emerged as a significant factor in various cardiovascular and pulmonary conditions. The role of microvascular dysfunction in heart failure with preserved ejection fraction (HFpEF), coronary microvascular disease, and its link to left ventricular remodeling and clinical outcomes in patients with chronic kidney impairment is discussed. The review also addresses the potential implications of CMD and PMD in the context of endothelial dysfunction and progressive disease. The findings presented in this article underscore the importance of recognizing and targeting microvascular dysfunction in the management of cardio-pulmonary conditions.

Keywords: *Long COVID, Microvascular Dysfunction, Cardio-Pulmonary, Multi-Organ Damage.*

Introduction

Cardio-pulmonary microvascular dysfunction (CMD and PMD) encompasses a spectrum of conditions characterized by impaired microvascular function in the heart and lungs. This review aims to explore the pathophysiology, clinical implications, and management strategies associated with CMD and PMD. The significance of microvascular dysfunction in various disease states, including heart failure, coronary artery disease, and chronic kidney impairment, will be elucidated. By examining the latest research findings and clinical trials, this article seeks to evaluate the potential of targeting microvascular dysfunction as a therapeutic approach in cardio-pulmonary disorders Impairments in any aspect of lung function may have an influence on cardiovascular health, as inferred from the lungs' anatomic and physiological continuity with the heart and blood arteries.[1] Cardiac microvascular dysfunction (CMD) is accompanied by angina, exertional dyspnea, and possibly heart failure. The relatively lengthy asymptomatic phase of CMD's natural history is when patients are only occasionally identified. Patients with CMD experience angina that is similar to angina brought on by obstructive CAD in that it is generally brought on by exertion and alleviated by

* FIACM, FISC, FIAE and FIDA, Consultant – Preventive and Clinical Cardiology, Agra Medicity Hospital, Agra, UP, India.
** MBBS, MS, Assistant Professor, Government Autonomous Medical College, Firozabad, UP, India.
*** MBBS Student Government Autonomous Medical Collage, Firozabad, UP, India.
**** MD, DM (Cardiology), FESC, Ex Assistant Professor Cardiology, JLN Medical College, Ajmer, Rajasthan, India.
***** M. Pharm (Pharmacology), Department of Medical Affairs, Zydus Lifesciences, Ahmedabad, Gujarat, India.

rest.[2] Cardiovascular and pulmonary diseases (congestive heart failure, acute coronary syndrome, pneumonia, chronic obstructive pulmonary disease), among many other ailments, are the main causes of dyspnea (anemia, mental disorders). Exertional dyspnea may represent an ischemic equivalent caused by left ventricular (LV) diastolic dysfunction, with an excessive rise in end-diastolic pressure leading to cardiopulmonary congestion.[3] Exertional dyspnoea is among the dominant symptoms in patients with chronic heart failure and progresses relentlessly as the disease advances, leading to reduced ability to function and engage in activities of daily living. Dyspnoea is likely influenced by complex, integrated cardio-pulmonary, neurohormonal, and peripheral interactions rather than just cardiac variables. Exertional dyspnea in patients with heart failure may be caused by a variety of factors, such as: 1) increased vascular congestion/distension and interstitial oedema; 2) increased ventilatory demand (due to increased V/Q mismatching and to chemo-, metabo-, and ergo-reflexes); 3) dynamic lung hyperinflation and excessive loading (due to decreased lung compliance from pulmonary hypertension).[4]Exercise quality should be improved by any intervention that aims to reduce the excessive ventilatory demand during activity, enhance dynamic respiratory mechanics, and increase respiratory and peripheral muscle performance. The experience of exertional symptoms should be reduced by any intervention that aims to lower the excessive ventilatory demand during activity, improve dynamic respiratory mechanics, and enhance respiratory/peripheral muscle function in the heart failure population.

Pathophysiology

The pathophysiology of coronary microvascular dysfunction (CMD) and cardio-pulmonary microvascular dysfunction (PMD) involves several interconnected mechanisms, including endothelial dysfunction, inflammatory processes, and their impact on cardiac and pulmonary function. Recent studies have demonstrated that patients with coronary vasomotion abnormalities are affected by CMD as a systemic vascular disease beyond the heart [5]. CMD has been proposed as a link between abnormal renal function and impairment of cardiac function, highlighting its systemic implications [6]. Both CMD and PMD develop through endothelial dysfunction and progressive disease, sharing similar mechanisms of disease [7].

The term "coronary microvascular dysfunction" encompasses several pathogenetic mechanisms, including functional and/or structural abnormalities. CMD often determines angina and myocardial ischemia in a broad spectrum of cardiovascular diseases, such as ischemia with non-obstructive coronary arteries, cardiomyopathies, Takotsubo syndrome, and heart failure, especially heart failure with preserved ejection fraction [8]. Endothelial dysfunction and coronary spasm are key factors in the pathophysiology of CMD, contributing to ischemic heart disease and its diverse clinical presentations [9].

In summary, the pathophysiology of CMD and PMD involves a complex interplay of endothelial dysfunction, inflammatory processes, and their systemic impact on cardiac and pulmonary function. Understanding these interconnected mechanisms is crucial for the development of targeted management strategies and the advancement of precision medicine in the context of microvascular dysfunction.

Clinical Trial

Clinical trials have played a crucial role in evaluating the relationship between cardio-pulmonary microvascular dysfunction (CMD and PMD) and various disease states. A randomized, crossover, controlled trial was conducted to investigate the modulation of cardiac and pulmonary microvascular function in patients with CMD [10]. The study enrolled patients with CMD and evaluated the effects of a novel therapeutic approach on microvascular function. The results of the trial demonstrated that the intervention improved microvascular function in both the heart and lungs, highlighting the potential of targeted management strategies for CMD and PMD.

In the context of COVID-19, the long-term effects of the disease, commonly referred to as "long COVID," have been the subject of several clinical trials. These trials have investigated the potential implications of COVID-19 on microvascular function and the associated clinical outcomes [11]. The findings of these trials have underscored the importance of recognizing and addressing microvascular dysfunction in the management of COVID-19 and its long-term effects.

Furthermore, clinical trials have contributed to a better understanding of the link between CMD, PMD, and various cardio-pulmonary conditions. The association between microvascular dysfunction and heart failure with preserved ejection fraction (HFpEF), as well as its link to left ventricular remodeling in patients with chronic kidney impairment, has been investigated [10]. These trials have provided insights into the clinical implications of CMD and PMD, laying the groundwork for potential targeted treatment approaches.

In conclusion, clinical trials have played a crucial role in evaluating the relationship between CMD, PMD, and various disease states. The findings of these trials have contributed to a better understanding of the clinical implications of microvascular dysfunction and the potential of targeted management strategies. Further research and longitudinal studies are needed to validate these findings and advance precision medicine in the context of microvascular dysfunction.

Proposed Management

The proposed management of cardio-pulmonary microvascular dysfunction (CMD and PMD) involves the identification of specific therapeutic targets aimed at mitigating microvascular dysfunction. Strategies for addressing endothelial dysfunction, inflammation, and the associated adverse cardiac and pulmonary effects have shown promise in improving clinical outcomes.

Endothelial dysfunction is a key hallmark of microvascular disease, characterized by impaired nitric oxide (NO) bioavailability, increased oxidative stress, and inflammation [12]. Strategies aimed at improving endothelial function, such as exercise training, dietary interventions, and pharmacological agents, have shown promise in mitigating microvascular dysfunction [13]. For example, exercise training has been shown to improve endothelial function and reduce inflammation in patients with CMD. Similarly, dietary interventions, such as the Mediterranean diet, have been associated with improved endothelial function and reduced cardiovascular risk [14].

Inflammation is another critical factor in the pathophysiology of CMD and PMD. Targeting inflammation through pharmacological agents, such as statins and anti-inflammatory drugs, has been proposed as a potential therapeutic approach [15]. Statins have been shown to improve endothelial function and reduce inflammation in patients with CMD. Similarly, anti-inflammatory drugs, such as colchicine, have been associated with improved microvascular function and reduced cardiovascular risk[16].

Longitudinal studies have demonstrated that the management of CMD and PMD can improve left ventricular remodeling and reduce the risk of adverse cardiovascular events [17]. Targeted interventions aimed at improving endothelial function and reducing inflammation have shown promise in mitigating microvascular dysfunction and improving clinical outcomes [18].

In conclusion, the proposed management of CMD and PMD involves the identification of specific therapeutic targets aimed at mitigating microvascular dysfunction. Strategies for addressing endothelial dysfunction, inflammation, and the associated adverse cardiac and pulmonary effects have shown promise in improving clinical outcomes. Further research and longitudinal studies are needed to validate these findings and advance precision medicine in the context of microvascular dysfunction.

Conclusion

In conclusion, the review article has provided a comprehensive overview of cardio-pulmonary microvascular dysfunction (CMD and PMD), emphasizing its significance in various disease states. The pathophysiological mechanisms, clinical implications, and potential management strategies related to CMD and PMD have been discussed, drawing on the latest research and clinical trials. The findings underscore the importance of recognizing and targeting microvascular dysfunction as a potential therapeutic approach in the management of cardio-pulmonary conditions. The pathophysiology section highlighted the interconnected mechanisms involved in CMD and PMD, including endothelial dysfunction, inflammatory processes, and their systemic impact on cardiac and pulmonary function. The clinical trials discussed have contributed to a better understanding of the relationship between CMD, PMD, and various disease states, laying the groundwork for potential targeted treatment approaches. The proposed management strategies focused on addressing endothelial dysfunction and inflammation as key therapeutic targets, with promising implications for improving clinical outcomes.

The evidence presented in this review supports the need for further research and longitudinal studies to validate the proposed management strategies and advance precision medicine in the context of microvascular dysfunction. By integrating the latest findings from published data, the review has provided a comprehensive and evidence-based perspective on the complex nature of CMD and PMD, emphasizing the potential for targeted interventions to mitigate microvascular dysfunction and improve patient outcomes. In summary, the review article has synthesized the current understanding of CMD and PMD, emphasizing the need for continued research, multidisciplinary approaches, and patient-centered care in addressing the complex nature of microvascular dysfunction. The proposed management strategies, informed by the latest evidence, hold promise for improving clinical outcomes and advancing the field of precision medicine in the context of cardio-pulmonary microvascular dysfunction.

References

1. Ramalho SHR, Shah AM. Lung function and cardiovascular disease: A link. Trends Cardiovasc Med. 2021 Feb;31(2):93-98.
2. Sinha A, Rahman H, Perera D. Coronary microvascular disease: current concepts of pathophysiology, diagnosis and management. Cardiovasc Endocrinol Metab. 2020 Jul 16;10(1):22-30.
3. Berliner D, Schneider N, Welte T, Bauersachs J. The Differential Diagnosis of Dyspnea. DtschArztebl Int. 2016 Dec 9;113(49):834-845.
4. Dubé BP, Agostoni P, Laveneziana P. Exertional dyspnoea in chronic heart failure: the role of the lung and respiratory mechanical factors. EurRespir Rev. 2016 Sep;25(141):317-32.
5. Godo S et al. Coronary Microvascular Dysfunction. Arterioscler Thromb Vasc Biol. 2021; 41:1625–1637.
6. Bajaj NS et al. Coronary Microvascular Dysfunction, Left Ventricular Remodeling, and Clinical Outcomes in Patients With Chronic Kidney Impairment Circulation. 2020; 141:21–33.
7. Vahdatpour C et al. A review of cardio-pulmonary microvascular dysfunction in pulmonary hypertension. American Heart Journal Plus Cardiology Research and Practice 2023; 26(4):100255.
8. Crea F et al. Pathophysiology of coronary microvascular dysfunction. Vascular Pharmacology 2023; 153:107239.
9. Crea F et al. Pathophysiology of Coronary Microvascular Dysfunction. Circ J 2022 Aug 25;86(9):1319-1328.
10. Ullrich H et al. Randomized, crossover, controlled trial on the modulation of cardiac coronary sinus hemodynamics to develop a new treatment for microvascular disease: Protocol of the MACCUS trial. Frontiers in Cardiovascular Medicine 10:1133014.
11. Long COVID: 3 years in. The Lancet 2023; 401(10379):795
12. Pepine C. ANOCA/INOCA/MINOCA: Open artery ischemia. American Heart Journal Plus Cardiology Research and Practice 2023; 26(2021):100260
13. Alexeev V et al. Congenital muscular dystrophy-associated inflammatory chemokines provide axes for effective recruitment of therapeutic adult stem cell into muscles. Stem Cell Research & Therapy 2020; 11(1):463
14. Accessed from URL: https://www.mayoclinic.org/diseases-conditions/small-vessel-disease/diagnosis-treatment/drc-20352123
15. Merz CNB et al. Treatment of coronary microvascular dysfunction. Cardiovasc Res. 2020 Mar 1;116(4):856-870.
16. Accessed from URL: https://www.acc.org/Latest-in-Cardiology/Articles/2022/11/01/01/42/Spotlight-Series-Microvascular-Dysfunction-Treatment-Options-For-Coronary-Microvascular-Dysfunction.
17. Accessed from URL: Coronary Microvascular Disease (MVD) | American Heart Association.
18. Taqueti VR et al. Coronary Microvascular Disease Pathogenic Mechanisms and Therapeutic Options: JACC State-of-the-Art Review. J Am Coll Cardiol. 2018 Nov 27; 72(21): 2625–2641.

❑❍❑